A Phase 2 interventional study of Romiplostim and Placebo in Lung Cancer, Chemotherapy-Induced Thrombocytopenia and Non-Small Cell Lung Cancer, sponsored by Amgen. Completed at 113 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-24.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2006, is one of 14 in phase 2, and was the 12th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 11 more countries
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 35 more countries
Ages 18–100
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 8 · Phase 4 1
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 145 across the 31 interventional studies, 102 across the 3 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Amgen that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 63 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Drug: Placebo · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin
Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin
Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin
Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Biological: Romiplostim · Drug: Gemcitabine · Drug: Carboplatin · Drug: Cisplatin
Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
Also known as: AMG 531, Nplate®
Placebo subcutaneous injection.
Intravenous infusion
Intravenous infusion
Intravenous infusion
Number of Participants With Adverse Events
This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.
Time frame: 4 months
Duration of Grade 3 or 4 Thrombocytopenia
The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \<50 x 10\^9/L) experienced during the first on study chemotherapy cycle by treatment group.
Time frame: 3 weeks
Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.
The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \< 50 x 10\^9/L, but ≥ 25 x 10\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \< 25 x 10\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.
Time frame: 3 weeks
Number of Participants With Platelet Transfusions
Number of participants who were administered platelet transfusions during first on study treatment cycle.
Time frame: 3 weeks
Platelet Count on Day 22
Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group
Time frame: Day 22
Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle
Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.
Time frame: 8 days
Participants were enrolled from 28 December 2006 through 11 August 2008.
| Milestone | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Started | 12 | 16 | 18 | 17 |
| Received study drug | 12 | 16 | 18 | 16 |
| Completed | 11 | 13 | 16 | 13 |
| Not completed | 1 | 3 | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Ineligibility determined | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Requirement for alternative therapy | 0 | 2 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.
| Participants | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Number of Participants With Adverse Events | 12 | 16 | 18 | 14 |
The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \<50 x 10\^9/L) experienced during the first on study chemotherapy cycle by treatment group.
| days | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Duration of Grade 3 or 4 Thrombocytopenia | 2.1 ± 3.3 | 3.6 ± 4.3 | 2.6 ± 3.9 | 2.1 ± 2.7 |
The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \< 50 x 10\^9/L, but ≥ 25 x 10\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \< 25 x 10\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.
| Participants | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle. | 5 | 7 | 7 | 7 |
Number of participants who were administered platelet transfusions during first on study treatment cycle.
| Participants | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Number of Participants With Platelet Transfusions | 1 | 4 | 1 | 1 |
Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group
| 10^9/L | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Platelet Count on Day 22 | 281.2 ± 116.0 | 222.6 ± 112.0 | 412.8 ± 295.2 | 336.0 ± 254.9 |
Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.
| Participants | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle | 2 | 4 | 4 | 5 |
Collected over From signing of the informed consent through 30 days after the last dose of investigational product or end of study, whichever is longer (up to 4 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/12 (8.3%) | 12/12 (100%) |
| Romiplostim 250 µg | — | 7/16 (43.8%) | 16/16 (100%) |
| Romiplostim 500 µg | — | 5/18 (27.8%) | 17/18 (94.4%) |
| Romiplostim 750 µg | — | 5/16 (31.3%) | 14/16 (87.5%) |
| Event | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 4/16 | 0/18 | 1/16 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 3/16 | 1/18 | 1/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/12 | 1/16 | 2/18 | 1/16 |
| NeutropeniaBlood and lymphatic system disorders | 0/12 | 1/16 | 0/18 | 0/16 |
| Cardiac failureCardiac disorders | 0/12 | 0/16 | 0/18 | 1/16 |
| CyanosisCardiac disorders | 0/12 | 0/16 | 0/18 | 1/16 |
| Abdominal painGastrointestinal disorders | 0/12 | 0/16 | 0/18 | 1/16 |
| VomitingGastrointestinal disorders | 0/12 | 0/16 | 0/18 | 1/16 |
| PyrexiaGeneral disorders | 0/12 | 0/16 | 0/18 | 1/16 |
| Catheter related infectionInfections and infestations | 0/12 | 1/16 | 0/18 | 1/16 |
| Event | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/12 | 7/16 | 7/18 | 5/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/12 | 8/16 | 8/18 | 8/16 |
| LeukopeniaBlood and lymphatic system disorders | 4/12 | 4/16 | 4/18 | 2/16 |
| NeutropeniaBlood and lymphatic system disorders | 2/12 | 3/16 | 3/18 | 5/16 |
| FatigueGeneral disorders | 1/12 | 5/16 | 4/18 | 1/16 |
| PyrexiaGeneral disorders | 0/12 | 5/16 | 2/18 | 0/16 |
| NauseaGastrointestinal disorders | 1/12 | 4/16 | 5/18 | 2/16 |
| VomitingGastrointestinal disorders | 3/12 | 4/16 | 1/18 | 1/16 |
| DizzinessNervous system disorders | 0/12 | 4/16 | 1/18 | 1/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/12 | 1/16 | 2/18 | 4/16 |
| Age Continuous(Years) | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 6.6 | 63.8 ± 10.8 | 62.5 ± 7.7 | 65.4 ± 8.2 | 63.1 ± 8.5 |
| Sex: Female, Male(Participants) | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 6 | 2 | 18 |
| Male | 6 | 12 | 12 | 15 | 45 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romiplostim 250 µg | Romiplostim 500 µg | Romiplostim 750 µg | Total |
|---|---|---|---|---|---|
| White or Caucasian | 12 | 15 | 18 | 17 | 62 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
Showing the first 100 of 113 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2006, a primary completion of Dec 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Carcinoma, Non-Small-Cell Lung →